X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, XOMA will get access to KIN-2787 (exarafenib), which is a potent and selective investigational small molecule pan-RAF inhibitor that is being evaluated for the BRAF/NRAS-mutated advanced or metastatic solid tumors.
Lead Product(s): Exarafenib,Binimetinib
Therapeutic Area: Oncology Product Name: KIN-2787
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Kinnate Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 16, 2024
Details:
XOMA acquired an economic interest in DSUVIA® (sufentanil sublingual tablet), an opioid agonist, indicated for use in adults, for the management of acute pain, from Talphera.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Talphera
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 18, 2024
Details:
Under the agreement, XOMA has acquired the royalty and milestone rights associated with two assets from LadRx Corporation, BRX-345 (arimoclomol), an oral therapeutic for Niemann-Pick disease type C, and aldoxorubicin, an albumin-linked formulation of doxorubicin.
Lead Product(s): Arimoclomol
Therapeutic Area: Rare Diseases and Disorders Product Name: BRX-345
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: LadRx
Deal Size: $58.6 million Upfront Cash: $5.0 million
Deal Type: Agreement January 11, 2024
Details:
Vabysmo (faricimab-svoa) is the first bispecific antibody which targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditions by neutralising Ang-2 and VEGF-A. It is being investigated for the treatment of retinal vein occlusion.
Lead Product(s): Faricimab
Therapeutic Area: Ophthalmology Product Name: Vabysmo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Blue Owl Capital
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 19, 2023
Details:
Under the agreement, XOMA acquired potential royalty economics related to DAY101 (tovorafenib), an investigational, oral, brain-penetrant, highly-selective type II RAF kinase inhibitor, being developed as a monotherapy for relapsed or progressive pediatric low-grade glioma.
Lead Product(s): Tovorafenib
Therapeutic Area: Oncology Product Name: DAY101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Day One Biopharmaceuticals
Deal Size: $59.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 31, 2023
Details:
The Company expects to use the proceeds to advance its lead novel LADR-based anti-cancer drug, LADR-7 (AE-keto-sulf07) towards an IND filing with the FDA.
Lead Product(s): AE-Keto-Sulf07
Therapeutic Area: Oncology Product Name: LADR7
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: LadRx
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 22, 2023
Details:
Through the aquisition, XOMA gains the milestone rights to IXINITY® [coagulation factor IX (recombinant)], which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B, from Aptevo Therapeutics.
Lead Product(s): Coagulation Factor IX (recombinant)
Therapeutic Area: Genetic Disease Product Name: Ixinity
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Aptevo Therapeutics
Deal Size: $9.6 million Upfront Cash: Undisclosed
Deal Type: Agreement March 30, 2023
Details:
Amolyt will advance pre-clinical development of AZP-40XX, an anti-PTHR1 monoclonal antibody, as potential treatments of primary hyperparathyroidism (PHPT) and humoral hypercalcemia of malignancy (HHM).
Lead Product(s): AZP-40XX
Therapeutic Area: Endocrinology Product Name: AZP-40XX
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amolyt Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 24, 2023
Details:
Under the terms of the agreement, XOMA has acquired all rights to ebopiprant held by ObsEva, including the Organon/ObsEva license agreement and the IP associated with the asset.
Lead Product(s): Ebopiprant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: OBE022
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: ObsEva
Deal Size: $490.0 million Upfront Cash: $15.0 million
Deal Type: Acquisition November 22, 2022
Details:
The Phase 3 trial will assess the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma. The milestone payment is a part of an agreement signed between Xoma and Novartis.
Lead Product(s): NIS793,Paclitaxel,Gemcitabine
Therapeutic Area: Oncology Product Name: NIS793
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $517.0 million Upfront Cash: $37.0 million
Deal Type: Agreement November 04, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
